Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05667116 · ClinicalTrials.gov registry record
eVusheld Assessment reaL wORld Effectiveness at UPMC
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 4,232
- Enrollment target
NCT05667116: Completed study, sponsored by AstraZeneca.
NCT05667116 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 4,232 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05667116 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 4,232 participants
- Enrollment target
Study Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the University of Pittsburgh Medical Center (UPMC) Health System.
Primary Outcome
To assess the effectiveness of EVUSHELD as PrEP against COVID-19 hospitalisation
Interventions
- DRUG EVUSHELD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,232 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2023-07-24 |
What the finished NCT05667116 record still lists
NCT05667116 is an observational study that tracks outcomes without assigning an intervention. Its 4,232 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which EVUSHELD is the first listed.
NCT05667116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05667116 about?
NCT05667116 is a clinical study titled "eVusheld Assessment reaL wORld Effectiveness at UPMC". An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient popu...
What is the current status of trial NCT05667116?
This trial is currently completed. The enrollment target is 4,232 participants. The study started on 2023-01-09. Estimated completion is 2023-07-24.
What interventions are being tested in trial NCT05667116?
The interventions under investigation include: EVUSHELD (DRUG).
Who is sponsoring clinical trial NCT05667116?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI